Skip to main content

Table 3 Description of patient cohort included in survival analysis (n = 63 patients)

From: Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients

  BCNU Control
Patient sample (n) 34 29
Age at 1st diagnosis (median; range) 56 (22–76) 62 (33–78)
Sex (male: female; n) 20:14 16:13
KPS (median; range) 8 (4–10) 6 (3–9)
MGMT promoter hypermethylation (%) 64,7 55,2
Overall survival (median: days (months)) 480 (15) 429 (14)
Progression-free survival (median: days (months)) 186 (6) 180 (5)
Survival after relapse (median: days (months)) 266 (9) 187 (6)
Complete resection at 1st surgery (%) 32,4 31
Radiotherapy at 1st diagnosis (%) 100 100
TMZ at 1st diagnosis (%) 14,7 17,2
Therapies other than BCNU at recurrence (re-resection, re-irradiation, TMZ, CCNU, thalidomide) 38,2 24,1
BCNU cycles (% of patients)   N/A
 - ≤6 88,2  
 - 7–10 5,9  
 - not determinable 5,9  
  1. N/A: not applicable